Cargando…

Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

BACKGROUND: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) was designed to monitor in vitro antimicrobial susceptibility to tigecycline and comparator agents. We present susceptibility data on Gram-negative organisms collected between 2005 and 2011 from nine United States census region...

Descripción completa

Detalles Bibliográficos
Autores principales: Denys, Gerald A, Callister, Steven M, Dowzicky, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851274/
https://www.ncbi.nlm.nih.gov/pubmed/24006892
http://dx.doi.org/10.1186/1476-0711-12-24
_version_ 1782294259651575808
author Denys, Gerald A
Callister, Steven M
Dowzicky, Michael J
author_facet Denys, Gerald A
Callister, Steven M
Dowzicky, Michael J
author_sort Denys, Gerald A
collection PubMed
description BACKGROUND: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) was designed to monitor in vitro antimicrobial susceptibility to tigecycline and comparator agents. We present susceptibility data on Gram-negative organisms collected between 2005 and 2011 from nine United States census regions. METHODS: T.E.S.T. was conducted using standardized CLSI methodologies or FDA-approved breakpoints. RESULTS: Tigecycline was highly active (MIC(90) ≤ 2 mg/L) against Enterobacteriaceae irrespective of species or region of collection (N = 25011). The isolates were also highly susceptible to the carbapenems when all regional data are combined, except for ESBL-producing Klebsiella pneumoniae (MIC(90) 16 mg/L) and Acinetobacter baumannii (MIC(90) ≥ 32 mg/L). In addition, 883 (30%) of 2900 A. baumannii isolates were classified as multidrug-resistant (MDR): these MDR organisms were most susceptible to tigecycline (MIC(90) 2 mg/L) and minocycline (MIC(90) 8 mg/L) when all regional data are considered together. Susceptibility patterns also varied widely among the regions CONCLUSIONS: The findings highlight the importance of monitoring antimicrobial susceptibility patterns and implementing effective methods to curb increased resistance and also confirm that additional studies to determine the efficacy of tigecycline in vivo, especially for treating infections with MDR organisms, are warranted.
format Online
Article
Text
id pubmed-3851274
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38512742013-12-06 Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) Denys, Gerald A Callister, Steven M Dowzicky, Michael J Ann Clin Microbiol Antimicrob Research BACKGROUND: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) was designed to monitor in vitro antimicrobial susceptibility to tigecycline and comparator agents. We present susceptibility data on Gram-negative organisms collected between 2005 and 2011 from nine United States census regions. METHODS: T.E.S.T. was conducted using standardized CLSI methodologies or FDA-approved breakpoints. RESULTS: Tigecycline was highly active (MIC(90) ≤ 2 mg/L) against Enterobacteriaceae irrespective of species or region of collection (N = 25011). The isolates were also highly susceptible to the carbapenems when all regional data are combined, except for ESBL-producing Klebsiella pneumoniae (MIC(90) 16 mg/L) and Acinetobacter baumannii (MIC(90) ≥ 32 mg/L). In addition, 883 (30%) of 2900 A. baumannii isolates were classified as multidrug-resistant (MDR): these MDR organisms were most susceptible to tigecycline (MIC(90) 2 mg/L) and minocycline (MIC(90) 8 mg/L) when all regional data are considered together. Susceptibility patterns also varied widely among the regions CONCLUSIONS: The findings highlight the importance of monitoring antimicrobial susceptibility patterns and implementing effective methods to curb increased resistance and also confirm that additional studies to determine the efficacy of tigecycline in vivo, especially for treating infections with MDR organisms, are warranted. BioMed Central 2013-09-05 /pmc/articles/PMC3851274/ /pubmed/24006892 http://dx.doi.org/10.1186/1476-0711-12-24 Text en Copyright © 2013 Denys et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Denys, Gerald A
Callister, Steven M
Dowzicky, Michael J
Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
title Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
title_full Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
title_fullStr Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
title_full_unstemmed Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
title_short Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
title_sort antimicrobial susceptibility among gram-negative isolates collected in the usa between 2005 and 2011 as part of the tigecycline evaluation and surveillance trial (t.e.s.t.)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851274/
https://www.ncbi.nlm.nih.gov/pubmed/24006892
http://dx.doi.org/10.1186/1476-0711-12-24
work_keys_str_mv AT denysgeralda antimicrobialsusceptibilityamonggramnegativeisolatescollectedintheusabetween2005and2011aspartofthetigecyclineevaluationandsurveillancetrialtest
AT callisterstevenm antimicrobialsusceptibilityamonggramnegativeisolatescollectedintheusabetween2005and2011aspartofthetigecyclineevaluationandsurveillancetrialtest
AT dowzickymichaelj antimicrobialsusceptibilityamonggramnegativeisolatescollectedintheusabetween2005and2011aspartofthetigecyclineevaluationandsurveillancetrialtest